Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14. https://doi.org/10.1016/s0140-6736(18)30010-2.

Article  PubMed  Google Scholar 

Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. https://doi.org/10.3322/caac.21834.

Article  PubMed  Google Scholar 

Globocan Cancer Observatory. Data version: 2022 [online]. https://gco.iarc.who.int/media/globocan/factsheets/populations/160-china-fact-sheet.pdf. Accessed 19 Apr 2024.

Llovet JM. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):7. https://doi.org/10.1038/s41572-021-00245-6.

Article  Google Scholar 

National Clinical Research Center for Infectious Diseases; Society of Hepatology, Beijing Medical Association; Translational Medicine Branch, China Association of Gerontology and Geriatrics. Expert consensus on precise diagnosis and management of primary hepatocellular carcinoma in advanced stage. Zhonghua Gan Zang Bing Za Zhi. 2023;31(9):910–20. https://doi.org/10.3760/cma.j.cn501113-20230717-00006.

Article  Google Scholar 

Chen PJ, Furuse J, Han KH, et al. Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts’ opinion. Liver Int. 2010;30(10):1427–38. https://doi.org/10.1111/j.1478-3231.2010.02292.x.

Article  PubMed  Google Scholar 

Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. https://doi.org/10.1056/NEJMoa0708857.

Article  CAS  PubMed  Google Scholar 

Zhang P, Zhang L, Xu K, et al. Evaluating the impact of PD-1 inhibitor treatment on key health outcomes for cancer patients in China. Int J Clin Pharm. 2024;46(2):429–38. https://doi.org/10.1007/s11096-023-01675-w.

Article  CAS  PubMed  Google Scholar 

Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–905. https://doi.org/10.1056/NEJMoa1915745.

Article  CAS  PubMed  Google Scholar 

Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Lancet Oncol. 2021;22(7):977–90. https://doi.org/10.1016/s1470-2045(21)00252-7.

Article  CAS  PubMed  Google Scholar 

Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77–90. https://doi.org/10.1016/s1470-2045(21)00604-5.

Article  CAS  PubMed  Google Scholar 

Merle P, Kudo M, Edeline J, et al. Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: longer term follow-up from the phase 3 KEYNOTE-240 trial. Liver Cancer. 2023;12(4):309–20. https://doi.org/10.1159/000529636.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):571–80. https://doi.org/10.1016/s1470-2045(20)30011-5.

Article  CAS  PubMed  Google Scholar 

Qin S, Kudo M, Meyer T, et al. Tislelizumab versus Sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial. JAMA Oncol. 2023;9(12):1651–9. https://doi.org/10.1001/jamaoncol.2023.4003.

Article  PubMed  PubMed Central  Google Scholar 

Chinese National Medical Products Administration. Notice of Drug Approval Documentation Delivered on January 2, 2024. [online]. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20240102151646109.html. Accessed 13 May 2024.

Tevimbra | European Medicines Agency (EMA) [online]. https://www.ema.europa.eu/en/medicines/human/EPAR/tevimbra#product-details. Accessed 12 Oct 2024.

Drug Approval Package: CTEVIMBRA. U.S. Food and Drug Administration (FDA) [online]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761232Orig1s000TOC.cfm. Accessed 12 Oct 2024.

Zheng Z, Lin Y, Cai H. Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis. Front Public Health. 2024;12:1356244. https://doi.org/10.3389/fpubh.2024.1356244.

Article  PubMed  PubMed Central  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

Article  CAS  PubMed  Google Scholar 

Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ. 2022;376: e067975. https://doi.org/10.1136/bmj-2021-067975.

Article  PubMed  PubMed Central  Google Scholar 

Su D, Wu B, Shi L. Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma. JAMA Netw Open. 2021;4(2): e210037. https://doi.org/10.1001/jamanetworkopen.2021.0037.

Article  PubMed  PubMed Central  Google Scholar 

Chinese Pharmaceutical Association. Chinese Pharmacoeconomic Evaluation Guidelines (2020). https://www.cpa.org.cn/cpadmn/attached/file/20201203/1606977380634185.pdf. Accessed 01 Mar 2024.

Oxford University Press. Methods for the Economic Evaluation of Health Care Programmes. https://nibmehub.com/opac-service/pdf/read/Methods%20for%20the%20Economic%20Evaluation%20of%20Health%20Care%20Programmes.pdf. Accessed 01 Mar 2024.

Statistical bulletin of National Economic and social development of the People’s republic of China in 2022. National Bureau of statistics of China (2022). [online]. https://data.stats.gov.cn/easyquery.htm?cn=C01&zb=A0201&sj=2022l. Accessed 5 Apr 2024.

Li Y, Liang X, Li H, et al. Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: a cost-effectiveness analysis. Cancer. 2022;128(22):3995–4003. https://doi.org/10.1002/cncr.34457.

Article  CAS  PubMed  Google Scholar 

Chen J, Tong X, Han M, et al. Cost-effectiveness of short-course radiation plus Temozolomide for the treatment of newly diagnosed glioblastoma among elderly patients in China and the United States. Front Pharmacol. 2021;12: 743979. https://doi.org/10.3389/fphar.2021.743979.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Messori A, Romeo MR, Fadda V et al. Costs and benefits in patients with NYHA class III heart failure treated with CardioMEMS in Italy. Glob Reg Health Technol Assess. 2024;11(1):105–7. https://doi.org/10.33393/grhta.2024.3018.

Article  PubMed  PubMed Central  Google Scholar 

Heine R, Mathijssen RHJ, Verbeek FAJ, et al. Market Entry Agreements for innovative pharmaceuticals subject to indication broadening: a case study for Pembrolizumab in The Netherlands. Value Health. 2024;27(10):1367–72. https://doi.org/10.1016/j.jval.2024.06.003.

Article  PubMed  Google Scholar 

Getaneh AM, Li X, Mao Z, et al. Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: evaluation for six European countries. Vaccine. 2023;41(9):1623–31. https://doi.org/10.1016/j.vaccine.2023.01.058.

Article  CAS  PubMed  Google Scholar 

Exchange-Rates.org. World currency exchange rates and historical rates. [online]. https://www.exchange-rates.org/exchange-rate-history/. Accessed 5 Apr 2024.

Wiksten A, Hawkins N, Piepho HP, et al. Nonproportional hazards in network meta-analysis: efficient strategies for model building and analysis. Value Health. 2020;23(7):918–27. https://doi.org/10.1016/j.jval.2020.03.010.

Article  PubMed  Google Scholar 

Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21(15):2175–97. https://doi.org/10.1002/sim.1203.

Article  PubMed  Google Scholar 

Cheng Y, Han L, Wu L, et al. Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: an international randomized phase 3 study. J Clin Oncol. 2022;40:8505. https://doi.org/10.1200/JCO.2022.40.16_suppl.8505.

Article  Google Scholar 

Rossi R, Murari A, Gaudio P, et al. Upgrading model selection criteria with goodness of fit tests for practical applications. Entropy (Basel). 2020. https://doi.org/10.3390/e22040447.

Article  PubMed  PubMed Central  Google Scholar 

National Health Commission of the People’s Republic of China [online]. http://www.nhc.gov.cn/. Accessed 18 Mar 2024.